Journal of International Oncology››2016,Vol. 43››Issue (1): 75-78.doi:10.3760/cma.j.issn.1673-422X.2016.01.021
Previous ArticlesNext Articles
Zhou Yinjie, Xiang Mingfei, Li Tao
Received:
2015-08-03Online:
2016-01-08Published:
2015-12-03Contact:
Li Tao E-mail:litaoxmf@126.comZhou Yinjie, Xiang Mingfei, Li Tao. Application of big medical data in cancer diagnosis and treatment[J]. Journal of International Oncology, 2016, 43(1): 75-78.
[1] Schilsky RL, Michels DL, Kearbey AH, et al. Building a rapid learning health care system for oncology: the regulatory framework of CancerLinQ[J]. J Clin Oncol, 2014, 32(22): 2373-2379. DOI:10.1200/JCO.2014.56.2124. [2]Helft M. Can big data cure cancer?[J]. Fortune, 2014, 170(2): 7074, 76, 78. [3]Tomczak K, Czerwińska P, Wiznerowicz M. The cancer genome atlas (TCGA): an immeasurable source of knowledge[J]. Contemp Oncol (Pozn), 2015, 19(1A): A68-A77. DOI:10.5114/wo.2014.47136. [4]Wilks C, Cline MS, Weiler E, et al. The cancer genomics hub (CGHub): overcoming cancer through the power of torrential data[J]. Database (Oxford), 2014, 2014: pii: bau093. DOI:10.1093/database/bau093. [5]International Cancer Genome Consortium, Hudson TJ, Anderson W, et al. International network of cancer genome projects[J]. Nature, 2010, 464(7291): 993-998. DOI:10.1038/nature08987. [6]Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes[J]. Science, 2013, 339(6127): 1546-1558. DOI:10.1126/science.1235122. [7]Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene[J]. Science, 2009, 324(5924): 217. DOI:10.1126/science.1171202. [8]Thirumurthi U, Shen J, Xia W, et al. MDM2mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer[J]. Sci Signal, 2014, 7(336): ra71. DOI:10.1126/scisignal.2005076. [9]Taylor CR. From microscopy to whole slide digital images: a century and a half of image analysis[J]. Appl Immunohistochem Mol Morphol, 2011, 19(6): 491-493. DOI:10.1097/PAI.0b013e318229ffd6. [10] Gu J, Taylor CR. Practicing pathology in the era of big data and personalized medicine[J]. Appl Immunohistochem Mol Morphol, 2014, 22(1): 1-9. DOI:10.1097/PAI.0000000000000022. [11] Muzny DM, Bainbridge MN, Chang K, et al. Comprehensive molecular characterization of human colon and rectal cancer[J]. Nature, 2012, 487(747): 330-337. DOI:10.1038/nature11252. [12] Kunz M. Genomic signatures for individualized treatment of malignant tumors[J]. Curr Drug Discov Technol, 2008, 5(1): 9-14. [13] Greene CS, Tan J, Ung M, et al. Big data bioinformatics[J]. J Cell Physiol, 2014, 229(12): 1896-1900. DOI:10.1002/jcp.24662. [14] Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated datamining platform[J]. Neoplasia, 2004, 6(1): 1-6. [15] Dou XL, Bai CM. Cancer biomarkers and personalized cancer medicine[J]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2015, 37(1): 113-117. DOI:10.3881/j.issn.1000-503X.2015.01.021. [16] Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009, 361(10): 947-957. [17] Incorvati JA, Shah S, Mu Y, et al. Targeted therapy for HER2 positive breast cancer[J]. J Hematol Oncol, 2013, 6(1): 23731980. DOI:10.1186/1756-8722-6-38. [18] Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer[J]. Clin Chem, 2015, 61(1): 112-123. DOI:10.1373/clinchem.2014.222679. [19] Cappelletti V, Appierto V, Tiberio P, et al. Circulating biomarkers for prediction of treatment response[J]. J Natl Cancer Inst Monogr, 2015 (51): 60-63. DOI:10.1093/jncimonographs/lgv006. [20] Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early and latestage human malignancies[J]. Sci Transl Med, 2014, 6(224): 224ra24. DOI:10.1126/scitranslmed.3007094. [21] Kim K. Big data key to improving health care[R]. AAMC Reporter, 2014, January. [22] Taitsman JK, Grimm CM, Agrawal S. Protecting patient privacy and data security[J]. N Engl J Med, 2013, 368(11): 977-979. DOI:10.1056/NEJMp1215258. [23] 李丹丹. 论个人医疗信息的法律保护[J]. 吉首大学学报: 社会科学版, 2015, 2(2): 87-93. DOI:10.13438/j.cnki.jdxb.2015.02.014. [24] Huang J, Yu Y. Bioinformatics of tumor molecular targets from big data[J]. Zhonghua Wei Chang Wai Ke Za Zhi, 2015, 18(1): 9-12. [25] Alyass A, Turcotte M, Meyre D. From big data analysis to personalized medicine for all: challenges and opportunities[J]. BMC Med Genomics, 2015, 8(1): 33. DOI:10.1186/s12920-015-0108-y. |
[1] | Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343. |
[4] | Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p, H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349. |
[5] | Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353. |
[6] | Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358. |
[7] | Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363. |
[8] | Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369. |
[9] | Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375. |
[10] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381. |
[11] | Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273. |
[12] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[13] | Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285. |
[14] | Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291. |
[15] | Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||